Cost-utility Analysis of Atezolizumab in the Second-Line Treatment of Metastatic Non-Small Cell Lung Cancer

ZHANG Chuan,RAN Fenglin,GU Linghan,LIU Yue,TIAN Panwen,LI Weimin

Herald of Medicine ›› 2022, Vol. 41 ›› Issue (12) : 1854-1859.

PDF(1871 KB)
中国科技论文统计源期刊　中文核心期刊  
美国《化学文摘》《国际药学文摘》
《乌利希期刊指南》
WHO《西太平洋地区医学索引》来源期刊  
日本科学技术振兴机构数据库（JST）
第七届湖北十大名刊提名奖  
PDF(1871 KB)
Herald of Medicine ›› 2022, Vol. 41 ›› Issue (12) : 1854-1859. DOI: 10.3870/j.issn.1004-0781.2022.12.023

Cost-utility Analysis of Atezolizumab in the Second-Line Treatment of Metastatic Non-Small Cell Lung Cancer

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2022, 41(12): 1854-1859 https://doi.org/10.3870/j.issn.1004-0781.2022.12.023

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(1871 KB)

Accesses

Citation

Detail
Sections
Recommended

/

〈 〉